This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MOUNTAIN VIEW, Calif.,
March 6, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal year ended
December 31, 2012, on
Tuesday, March 26, 2013, following the close of the U.S. financial markets. On
Tuesday, March 26, 2013, at
5:00 p.m. Eastern Time /
2:00 p.m. Pacific Time, the Company will host an investor conference call and live webcast to provide a company update and discuss the financial results. The conference call, live webcast and archived replay are open to all interested parties.
To access the conference call via the Internet, go to
www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at
To access the live conference call via phone, dial 888-679-8035. International callers may access the live call by dialing +1-617-213-4848. The reference number to enter the call is 99281086.
The replay of the conference call may be accessed via the Internet, at
www.alexza.com, or via phone at 888-286-8010
for domestic callers or +1-617-801-6888 for international callers. The reference number for the replay of the call is 44796025. A replay of the call will be available for two weeks following the event.
About Alexza Pharmaceuticals, Inc.Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions, including agitation, acute repetitive seizures and insomnia. Alexza's products are based on the Staccato® system, a hand-held inhaler that is designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset with ease and convenience for patients.
Staccato loxapine) is Alexza's first approved product, which was approved by the U.S. Food and Drug Administration in
December 2012 and by the European Medicines Agency in February 2013.
Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for ADASUVE in
Russia and the Commonwealth of Independent States countries. The commercial launch of ADASUVE is planned for the third quarter 2013 in the U.S. and
For more information about Alexza, the
Staccato system technology or the Company's development programs, please visit
www.alexza.com. For more information about ADASUVE, please visit
ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.